The most common ones include nausea, vomiting, diarrhea and constipation, especially when you first start the medication
The NHS followed more than 200,000 participants over a period of up to 30 years (110)
SOURCE: JAMA Network Open , Oct
Abbreviations CVE: Cardiovascular event EHR: Electronic health record GLP-1RA: Glucagon-like peptide-1 receptor agonist MACE: Major adverse cardiovascular events NAFLD: Non-alcoholic fatty liver disease NASH: Non-alcoholic steatohepatitis PCI: Percutaneous coronary intervention PSM: Propensity score matching SGLT2: Sodiumglucose cotransporter 2 SMD: Standardised mean difference TG: Triacylglycerol References Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes
Recommended dosage: 0.05% 0.5% in final cosmetic products